Literature DB >> 17163582

The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients.

Chung-Hua Hsu1, Kung-Chang Hwang, Chung-Liang Chao, Steve G N Chang, Cheng-Chin Ker, Lin-Chen Chien, Mei-Shang Ho, Jaung-Geng Lin, Yi-Ming Chen, Pesus Chou.   

Abstract

Chinese medicine (CM) has been used to control infectious diseases for thousands of years. In 2003 outbreaks of severe acute respiratory syndrome (SARS) occurred in China, Hong Kong and Taiwan. In view of the possible beneficial effect of CM on SARS, we conducted this study to examine whether CM is of any benefit as a supplementary treatment of SARS. Four severe laboratory-confirmed SARS patients received routine western-medicine treatment plus different supplementary treatment: CM A, CM B and CM C (placebo control). We reported the course of the cases in terms of changes in chest radiographic scores. Case 1 treated as a placebo control passed away on the 9th day after onset of disease. The other three cases treated with CM A or CM B survived. The initial findings seemed to indicate a favorable effect of CM on management of SARS. The findings need to be verified with a larger sample. Using CM as a supplementary treatment of severe SARS seems to indicate that natural herbal medicine can be used against avian influenza. Hence, such related experience or clinical trials should be taken into consideration when facing the possible outbreak of avian influenza in the future.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163582     DOI: 10.1142/S0192415X06004405

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  9 in total

Review 1.  Therapeutic opportunities of edible antiviral plants for COVID-19.

Authors:  Bhoomika Patel; Supriya Sharma; Nisha Nair; Jaseela Majeed; Ramesh K Goyal; Mahaveer Dhobi
Journal:  Mol Cell Biochem       Date:  2021-02-15       Impact factor: 3.396

2.  The Traditional Chinese Medicine Formula Jing Guan Fang for Preventing SARS-CoV-2 Infection: From Clinical Observation to Basic Research.

Authors:  Yueh-Hsin Ping; Hsin Yeh; Li-Wei Chu; Zhi-Hu Lin; Yin-Chieh Hsu; Lie-Chwen Lin; Chung-Hua Hsu; Shu-Ling Fu; Tung-Yi Lin
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

3.  Exploration of molecular targets and mechanisms of Chinese medicinal formula Acacia Catechu -Scutellariae Radix in the treatment of COVID-19 by a systems pharmacology strategy.

Authors:  Tian Feng; Meng Zhang; Qiong Xu; Fan Song; Libin Wang; Shouchang Gai; Haifeng Tang; Siwang Wang; Liying Zhou; Hua Li
Journal:  Phytother Res       Date:  2022-07-20       Impact factor: 6.388

4.  The Potential Complementary Role of Using Chinese Herbal Medicine with Western Medicine in Treating COVID-19 Patients: Pharmacology Network Analysis.

Authors:  Yi-Chin Lu; Liang-Wei Tseng; Yu-Chieh Huang; Ching-Wei Yang; Yu-Chun Chen; Hsing-Yu Chen
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-26

5.  Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.

Authors:  Lisa M Alleva; Charles Cai; Ian A Clark
Journal:  Evid Based Complement Alternat Med       Date:  2009-09-24       Impact factor: 2.629

Review 6.  Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.

Authors:  Yujun Tang; Jiajia Liu; Dingyi Zhang; Zhenghao Xu; Jinjun Ji; Chengping Wen
Journal:  Front Immunol       Date:  2020-07-10       Impact factor: 7.561

Review 7.  The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic?

Authors:  Andréa D Fuzimoto; Ciro Isidoro
Journal:  J Tradit Complement Med       Date:  2020-05-30

8.  A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study.

Authors:  Keng-Chang Tsai; Yi-Chia Huang; Chia-Ching Liaw; Chia-I Tsai; Chun-Tang Chiou; Chien-Jung Lin; Wen-Chi Wei; Sunny Jui-Shan Lin; Yu-Hwei Tseng; Kuo-Ming Yeh; Yi-Ling Lin; Jia-Tsrong Jan; Jian-Jong Liang; Chun-Che Liao; Wen-Fei Chiou; Yao-Haur Kuo; Shen-Ming Lee; Ming-Yung Lee; Yi-Chang Su
Journal:  Biomed Pharmacother       Date:  2020-11-19       Impact factor: 6.529

Review 9.  Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis.

Authors:  Caiyun Hu; Mingming Liang; Fengfeng Gong; Bin He; Dongdong Zhao; Guoliang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-17       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.